Print Page      Close Window     

Investors

SEC Filings

6-K
OBSEVA SA filed this Form 6-K on 03/30/2018
Entire Document
 


LOGO

 

PROLONG Ph2a Study (Parts A and B) Preliminary safety Final Part A Main study end End of Infant FU & PK analysis Main analysis Part A Dosing for 7d Maternal + neonatal FU 24-month Infant FU 8 patients Open-label: Atosiban + OBE022 Final Part B Main analysis Part B Dosing for 7d Maternal + neonatal FU 24-month Infant FU 60 patients + up to 60 patients Double-blind: Atosiban + OBE022 vs Atosiban + PLACEBO